Hansen Gwenn, CSO, reported a transaction classified as exercise at Nurix Therapeutics, Inc. involving 1452.000000 shares for an estimated $2700.72. Reported holdings after the transaction were 118679.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Scientific Officer
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
0 other filings
0 recent txs